
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
The American Journal of Managed Care
about 25 years ago
Medical and Surgical Management of Coronary Artery Disease in Womenabout 25 years ago
A Pharmacy-Based Approach to Cholesterol Managementabout 25 years ago
Can Health Systems Heal Themselves?about 25 years ago
Chronic Pelvic Pain in Women





